Prescription drug subsidies in Australia and New Zealand

Australian Prescriber

Volumn 33, Issue 1, 2010, Pages 2-4

  Morgan, Steve ^a   Boothe, Katherine ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cost of drugs; Drug evaluation; Drug regulation; Pharmaceutical Benefits Scheme

Indexed keywords

GENERIC DRUG;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MANUFACTURE; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; NEW ZEALAND; PRESCRIPTION;

EID: 76149101619     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2010.001     Document Type: Editorial

References (11)

1. Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 2008;188:26-8.
2. Morgan S, Kennedy J, Boothe K, McMahon M, Watson D, Roughead E. Toward an understanding of high performance pharmaceutical policy systems: a 'triple-A' framework and example analysis. Open Health Serv Policy J 2009;2:1-9.
3. Hall J. Incremental change in the Australian health care system. Health Aff (Millwood) 1999;18:95-110.
4. Reekie WD. Drug prices in the UK, USA, Europe and Australia. Aust Econ Pap 1984;23:71-8.
5. Harvey K, Murray M. Medicinal drug policy. In: Gardner H, editor. The politics of health: the Australian experience. Melbourne: Churchill Livingstone; 1995.
6. Pharmaceutical Management Agency (PHARMAC). PHARMAC releases data on Australia vs NZ comparison [media release]. 2006.
7. Thomas MC, Mann J, Williams S. The impact of reference pricing on clinical lipid control. N Z Med J 1998;111:292-4.
8. Austvoll-Dahlgren A, Aaserud M, Vist GE, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database of Systematic Reviews 2008;1:CD007017.
9. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005;11:730-40.
10. Adams AS, Soumerai SB, Ross-Degnan D. The case for a medicare drug coverage benefit: a critical review of the empirical evidence. Annu Rev Public Health 2001;22:49-61.
11. Faunce T, Lofgren H. Drug price reforms: the new F1-F2 bifurcation. Aust Prescr 2007;30:138-40.